LEXINGTON, Mass., May 03, 2010 (BUSINESS WIRE) –AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that David
Arkowitz, Executive Vice President, Chief Financial Officer and Chief
Business Officer will present an overview of the Company at the Bank of
America Merrill Lynch 2010 Healthcare Conference on May 11 at 3:00 p.m.
ET. The Conference is being held May 11-13, 2010 in New York City.
A live webcast of the presentation will be accessible through the
Investors section of the Company’s website at www.amagpharma.com.
Following the conference, the webcast will be archived on the AMAG
Pharmaceuticals, Inc. website until May 25, 2010.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes
its proprietary technology for the development and commercialization of
a therapeutic iron compound to treat iron deficiency anemia and novel
imaging agents to aid in the diagnosis of cancer and cardiovascular
disease. On June 30, 2009, AMAG received approval from the U.S. Food and
Drug Administration to market Feraheme(R) (ferumoxytol)
Injection for intravenous (IV) use for the treatment of iron deficiency
anemia in adult chronic kidney disease patients. For additional company
and product information, please visit www.amagpharma.com.
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
SOURCE: AMAG Pharmaceuticals, Inc.
Carol Miceli, 617-498-3361